Share useful research with your peers
in · Share on LinkedIn ↗
COMPANY RESEARCH

Axsome Therapeutics, Inc.

Axsome Therapeutics is a U.S. biopharmaceutical company developing and commercializing medicines for central nervous system disorders. Its research focuses on pharmacological interventions for neurological and psychiatric conditions, supported by clinical development and commercialization operations. The company's therapeutic interests include disorders affecting mood, cognition, sleep and related neural functions. Axsome is headquartered in New York and its shares are listed on Nasdaq under AXSM. Its work spans the identification of treatment approaches, clinical assessment of therapies and delivery of medicines to patients with neurological or psychiatric needs. This combination of research and commercial capabilities defines its biopharmaceutical operating model.

Company at a glance

Corporate information

Company entity
Axsome Therapeutics, Inc.
Headquarters / principal office
United States
Sources (1)
Founded
Not verified
Ownership / capital status
Publicly tradedPublicly listed
LinkedIn company page
Independent company page not verified

Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.

Listed issuer and R&D focus

Nasdaq: AXSM

CNS pharmacology · small molecules

psychiatry · neurology · sleep disorders

Last independently verified:

Disease tags match recorded text mentions and require program-level verification.

Technology, programs & evidence

Axsome Therapeutics is a U.S. biopharmaceutical company developing and commercializing medicines for central nervous system disorders. Its research focuses on pharmacological interventions for neurological and psychiatric conditions, supported by clinical development and commercialization operations. The company's therapeutic interests include disorders affecting mood, cognition, sleep and related neural functions. Axsome is headquartered in New York and its shares are listed on Nasdaq under AXSM. Its work spans the identification of treatment approaches, clinical assessment of therapies and delivery of medicines to patients with neurological or psychiatric needs. This combination of research and commercial capabilities defines its biopharmaceutical operating model.

Business, technology & evidence

  • SecuritiesNasdaq: AXSM

Individual program detail is not recorded. Consult the original sources below.

Related news & literature

Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.

Showing 0 / 0 related items

No cataloged update explicitly mentions this company.

Same-field reading (not company-specific)

Research this company together

Discussions are for signed-in members. Personal notes remain separate from company research.

Sign in to join

Sources & open questions

    1. Official issuer and R&D disclosure · Axsome Therapeutics, Inc. ↗Axsome Therapeutics, Inc. ·

    Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.

    AI assistant ↗